HS-20093

• Hansoh Pharma's B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration. • The designation is for the treatment of small cell lung cancer (SCLC), a disease with significant unmet medical need. • This development follows a licensing agreement with GlaxoSmithKline, which is conducting global trials of HS-20093. • The Breakthrough Therapy Designation could significantly impact Hansoh’s market position and attract investor interest.

GSK's Q3 2024 sales reached £8.0 billion, with a 2% CER increase, driven by strong performance in Specialty Medicines, offsetting lower Vaccines sales.

Durvalumab consolidation post-chemoradiotherapy significantly improves overall and progression-free survival in limited-stage SCLC, marking a breakthrough in nearly three decades.

• HS-20093, a B7-H3-targeted antibody-drug conjugate, demonstrated encouraging antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). • In the ARTEMIS-001 trial, HS-20093 achieved an overall response rate (ORR) of 61.3% at 8 mg/kg and 50.0% at 10 mg/kg in ES-SCLC patients. • The disease control rate (DCR) was high in both cohorts, with 80.6% for the 8.0-mg/kg group and 95.5% for the 10.0-mg/kg group, indicating effective disease stabilization. • The safety profile of HS-20093 was manageable, with hematologic adverse events being the most common, and the 8.0-mg/kg dose showing a better safety profile.

The FDA granted Breakthrough Therapy Designation to GSK5764227 for extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy.